Hyperbilirubinemia is a prevalent problem in babies that necessitates medical attention. Probiotic administration as adjuvant therapy may have a positive impact on the pathological neonatal unconjugated hyperbilirubinemia.
Neonatal jaundice is a common health care issue that affects approximately 9% of newborns after birth. The percent of neonates who acquire jaundice in the first week of their birth is about 60%. while the percent of breasted neonates who develop jaundice during the first month of their birth is about 10%. Phototherapy is the standard therapy for neonates who develop pathological jaundice, as it can alter bilirubin structure and increase its excretion. Probiotics can also be used for the treatment of jaundice. The efficacy of probiotics depends on their ability to pass across the GIT and cause colonization in the intestinal lumen. Hence, it leads to a decrease in the bacterial growth in the small bowel, a reduction in the function of the gastrointestinal barrier, and a regulation of the immune system of the host.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
44
drops of probiotic supplement containing bacillus clausil spores (Enterogermania Amp 2 Billion/5Ml )
the change in the measured total bilirubin, direct bilirubin, and Indirect Bilirubin.
Time frame: up to 4 weeks
The change in serum concentration of the Human Tumor Necrosis Factor Alpha (TNFa)
Time frame: up to 4weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.